Scleromyxedema, a positive effect with thalidomide

Dermatology

Volumn 213, Issue 2, 2006, Pages 150-152

  Jacob, Sharon E ^a,c   Fien, Sari ^a   Kerdel, Francisco A ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b Florida Academic Dermatology Centers   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppressives; Scleromyxedema; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; METHOTREXATE; RETINOID; THALIDOMIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; SCLEROMYXEDEMA;

ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PARAPROTEINS; SCLEROMYXEDEMA; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 33747030601     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093856     Document Type: Article

References (36)

1. Rongioletti F, Rebora A: Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273-281.
2. Dinneen AM, Dicken CH: Scleromyxedema. J Am Acad Dermatol 1995;33:37-43.
3. Jackson EM, English JC 3rd: Diffuse cutaneous mucinoses. Dermatol Clin 2002;20:493-501.
4. Harper RA, Rispler J: Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978;199:545-547.
5. Yaron M, Yaron I, Yust I, Brenner S: Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985;12:171-175.
6. Chanda JJ: Scleromyxedema. Cutis 1979;24:549-552.
7. Bonnetblanc JM, Bedane C: Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol 1991;127:1733-1734.
8. Horn KB, Horn MA, Swan J, Singhal S, Guitart J: A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 2004;51(2 suppl):S120-S123.
9. Rayson D, Lust JA, Duncan A, Su WP: Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999;74:481-484.
10. Farr PM, Ive FA: PUVA treatment of scleromyxedema. Br J Dermatol 1984;110:347-350.
11. Lowe NJ, Dufton PA, Hunter RD, Vickers CF: Electron-beam treatment of scleromyxedema. Dermatology 1982;106:449-453.
12. Milam CP, Cohen LE, Fenske NA, Ling NS: Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988;19:469-477.
13. Hisler BM, Savoy LB, Hasimoto K: Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991;24:854-857.
14. Keong CH, Asaka Y, Fukuro S, Miyamoto C, Katsumata M, Iino Y, Komiya T: Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol 1990;22:842-844.
15. Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH: Scleromyxedema: response to high-dose intravenous immunoglobulin. J Am Acad Dermatol 2000;43:403-408.
16. Berkson M, Lazarus GS, Uberti-Benz M, Rock AH: Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol 1991;25:724.
17. Kaufman D, Truhan AP, Roenigk HH Jr: Scleromyxedema: systemic manifestations and cosmetic improvement from dermabrasion. Cutis 1987;39:321-324.
18. Feldman P, Shapiro L, Pick AI, Slatkin MH: Scleromyxedema: a dramatic response to melphalan. Arch Dermatol 1969;99:51-56.
19. Harris RB, Perry HO, Kyle RA, Winkelmann RK: Treatment of scleromyxedema with melphalan. Arch Dermatol 1979;115:295-299.
20. Bata-Csorgo Z, Husz S, Foldes M, Korom I, Molnar K, Morvay M, Dobozy A: Scleromyxedema. J Am Acad Dermatol 1999;41:343-346.
21. Saigoh S, Tashiro A, Fujita S, Matsui M, Shibata S, Takeshita H, Duan H, Moroi Y, Urabe K, Koga T, Furue M: Successful treatment of intractable scleromyxedema with cyclosporine A. Dermatology 2003;207:410-411.
22. Davis LS, Sanal S, Sangueza OP: Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol 1996;35:288-290.
23. Howsden SM, Herndon JH Jr, Freeman RG: Lichen myxedema: a dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 1975;111:1325-1330.
24. Jessen RT, Straight M, Becker LE: Lichen myxedematosus: treatment with cyclophosphamide. Int J Dermatol 1978;17:833-839.
25. Verity MA, Toop J, McAdam LP, et al: Scleromyxedema myopathy: histochemical and electron microscopic observations. Am J Clin Pathol 1978;69:446-451.
26. McAdam LP, Pearson CM, Pitts WH, et al: Papular mucinosis with myopathy, arthritis, and eosinophilia: a histopathologic study. Arthritis Rheum 1977;20:989-996.
27. Wieder JM, Barton KL, Baron JM, Soltani K: Lichen myxedematosus treated with chlorambucil. Dermatol Surg Oncol 1993;19:475-476.
28. Tschen JA, Chang JR: Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999;40:303-307.
29. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
30. Stirling DI: Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1988;17:231-242.
31. Tseng S, Pak G, Washenik K, et al: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-979.
32. Radomsky CL, Levine N: Thalidomide. Dermatol Clin 2001;19:87-103.
33. Calabrese L, Fleischer AB: Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-495.
34. Sander CS, Kaatz M, Elsner P: Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. Dermatology 2004;208:149-152.
35. Kolivras A, De Maubeuge J, Andre J, Song M: Thalidomide in refractory vulvar ulcerations associated with Crohn's disease. Dermatology 2003;206:381-383.
36. Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M: Neurological toxicity of long-term (>1 years) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212-216.